Search Results - "Alvarez, R.H."

Long-term treatment efficacy in primary inflammatory breast cancer by hormonal receptor- and HER2-defined subtypes by Masuda, H., Brewer, T.M., Liu, D.D., Iwamoto, T., Shen, Y., Hsu, L., Willey, J.S., Gonzalez-Angulo, A.M., Chavez-MacGregor, M., Fouad, T.M., Woodward, W.A., Reuben, J.M., Valero, V., Alvarez, R.H., Hortobagyi, G.N., Ueno, N.T.

“…Subtypes defined by hormonal receptor (HR) and HER2 status have not been well studied in inflammatory breast cancer (IBC). We characterized clinical parameters…”
Get full text

Phase II study of olaparib + durvalumab (MEDIOLA): Updated results in germline BRCA-mutated platinum-sensitive relapsed (PSR) ovarian cancer (OC) by Drew, Y., Kaufman, B., Banerjee, S., Lortholary, A., Hong, S.H., Park, Y.H., Zimmermann, S., Roxburgh, P., Ferguson, M., Alvarez, R.H., Domchek, S., Gresty, C., Angell, H.K., Ros, V Rocher, Meyer, K., Lanasa, M., Herbolsheimer, P., de Jonge, M.

Get full text

Pretreatment Staging PET/CT in Patients with Inflammatory Breast Cancer Influences Radiation Treatment Field Designs by Walker, G.V, Yang, W, Rohren, E.M, Valero, V, Woodward, W.A, Alvarez, R.H, Lucci, A, Ueno, N.T, Buchholz, T.A

Get full text

Improved tolerability of neratinib in patients with HER2-positive early-stage breast cancer: the CONTROL trial by Barcenas, C.H., Hurvitz, S.A., Di Palma, J.A., Bose, R., Chien, A.J., Iannotti, N., Marx, G., Brufsky, A., Litvak, A., Ibrahim, E., Alvarez, R.H., Ruiz-Borrego, M., Chan, N., Manalo, Y., Kellum, A., Trudeau, M., Thirlwell, M., Garcia Saenz, J., Hunt, D., Bryce, R., McCulloch, L., Rugo, H.S., Tripathy, D., Chan, A., Carcas, L., Castrellon, A., Chan, D., Cheong, K., Choi, B., Coleman, M., Conlin, A., Dichmann, R., Ellison, D., Erickson, N., Gore, I., Hansen, V., Huang, D., Hufnagel, D., Kass, F., Kendall, S.D., Kozloff, M., Lawler, W., Nahum, K.D., Pistilli, B., Reyes, E., Seeger, J., Somer, R., Chiu, E. Tan, Thomas, G., Tkaczuk, K., Vaziri, I., Wade, J., Wilkinson, M.

“…Neratinib is an irreversible pan-HER tyrosine kinase inhibitor approved for extended adjuvant treatment in early-stage HER2-positive breast cancer based on the…”
Get full text

Mutational landscape of gynecologic cancers identified by prospective clinical sequencing in a nationwide cancer network by Schink, J.C., Alvarez, R.H., Elvin, J.A., Moran, A., Manahan, K.J., Geisler, J.P., Chura, J., McIntosh, D.G., Godbee, N., Tan, B.A., Zook, S., Markman, M.

Get full text

1190PD - Phase II study of olaparib + durvalumab (MEDIOLA): Updated results in germline BRCA-mutated platinum-sensitive relapsed (PSR) ovarian cancer (OC) by Drew, Y., Kaufman, B., Banerjee, S., Lortholary, A., Hong, S.H., Park, Y.H., Zimmermann, S., Roxburgh, P., Ferguson, M., Alvarez, R.H., Domchek, S., Gresty, C., Angell, H.K., Ros, V Rocher, Meyer, K., Lanasa, M., Herbolsheimer, P., de Jonge, M.

“…Olaparib (Lynparza®) is a poly(ADP-ribose) polymerase (PARP) inhibitor approved as maintenance treatment of PSR OC. MEDIOLA assessed olaparib in combination…”
Get full text

Circulating tumor cells in immunohistochemical subtypes of metastatic breast cancer: lack of prediction in HER2-positive disease treated with targeted therapy by Giordano, A., Giuliano, M., De Laurentiis, M., Arpino, G., Jackson, S., Handy, B.C., Ueno, N.T., Andreopoulou, E., Alvarez, R.H., Valero, V., De Placido, S., Hortobagyi, G.N., Reuben, J.M., Cristofanilli, M.

“…Circulating tumor cells (CTCs) are associated with inferior prognosis in metastatic breast cancer (MBC). We hypothesized that the relationship between CTCs and…”
Get full text

An open-label, phase II basket study of olaparib and durvalumab (MEDIOLA): Results in germline BRCA-mutated (gBRCAm) platinum-sensitive relapsed (PSR) ovarian cancer (OC) by Drew, Y., de Jonge, M., Hong, S.H., Park, Y.H., Wolfer, A., Brown, J., Ferguson, M., Gore, M.E., Alvarez, R.H., Gresty, C., Angell, H., Meyer, K., Learoyd, M., Tang, M., Lanasa, M., Herbolsheimer, P., Domchek, S.M.

Get full text

Mutational landscape of metastatic cancers discovered from prospective clinical sequencing at community practice cancer program by Alvarez, R.H., Moran, A., Meiri, E., Loaiza-Bonilla, A., Parikh, A.R., Crilley, P., Elvin, J., Reddy, P., Miller, V.A., Zook, S., Ali, S.M., Markman, M.

Get full text

Early results from an open-label phase 1b/II study of eribulin mesylate (EM) + pegvorhyaluronidase alfa (PEGHP20) combination for the treatment of patients with HER2-negative, high-hyaluronan (HA) metastatic breast cancer (MBC) by Shum, M., Assikis, V.J., Savulsky, C., Zhu, W., Iyer, P., Xing, D., Berman, C., Lokker, N.A., Alvarez, R.H.

Get full text

Detection of targetable kinase fusions in 7260 patients in an integrated cancer system by Parikh, A., Ali, S.M., Moran, A., Crilley, P., Schrock, A.B., Tan, A., Reddy, P., Miller, V.A., Ross, J.S., Zook, S., Alvarez, R.H., Markman, M.

Get full text

MEDIOLA: A phase I/II trial of olaparib (PARP inhibitor) in combination with durvalumab (anti-PD-L1 antibody) in pts with advanced solid tumours - new ovarian cancer cohorts by Penson, R T, Drew, Y, de Jonge, M J A, Hong, S-H, Park, Y H, Wolfer, A, Brown, J, Ferguson, M, Gore, M E, Alvarez, R H, Kaufman, B, Gresty, C, Angell, H K, Meyer, K, Lanasa, M, Herbolsheimer, P, Domchek, S

Get full text

Comprehensive analysis of factors impacting risks and outcomes of therapy-related myeloid neoplasms following breast cancer treatment by Sevcikova, K, Zhuang, Z, Garcia-Manero, G, Alvarez, R H, Kantarjian, H M, Mego, M, Albarracin, C, Tang, G, Strom, S S, Medeiros, L J, Hortobagyi, G N, Reuben, J M, Khoury, J D

Get full text

MLN8237 (ALISERTIB), An Investigational Aurora a Kinase Inhibitor, in Patients (PTS) with Non-Small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC), Breast Cancer (BRC), Head and Neck Squamous Cell Carcinoma (HNSCC), And Gastroesophageal Cancer (GE): Emerging Phase (PH) 2 Results by Melichar, B., Lee, P., Alvarez, R.H., Degardin, M., Bennouna, J., Schusterbauer, C., Zhang, B., Benaim, E., Rosen, P.

Get full text

Efficacy of the Ovsynch treatment associated to fixed-time artificial insemination in Bos taurus and Bos indicus herds by Alvarez, R.H, Martinez, A.C, Carvalho, J.B.P. de, Arcaro, J.R.P, Pires, R.M.L, Oliveira, C.A. de

Get full text

In vitro production of bovine embryos: utilization of different gonadotropin sources for in vitro maturation of oocytes by Coelho, L. de A, Esper, C.R, Alvarez, R.H, Vantini, R, Almeida Júnior, I.L

Get full text

Endocrine profiles and ovulation rate of cows superovulated with FSH following passive immunization against steroid free-bovine follicular fluid by Alvarez, R.H., Carvalho, J.B.P., Rosa e Silva, A.A., Perone, C.N., Ribela, M.T.C.P., Fiflio, E.B.Oliveira

Get full text

Ovarian response of buffaloes (Bubalus bubalis) superovulated with PMSG or FSH-P by Alvarez R.H, Nogueira J.R, Araujo Filho A.M

Get full text